Page 120 - Read Online

Page 8 of 9 Malapelle et al. J Transl Genet Genom 2019;3:3. I https://doi.org/10.20517/jtgg.2018.29

Copyright
© The authors 2019.

REFERENCES
1. Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer
2013;82:179-89.
2. Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact
of targeted therapy with ALK inhibitors. Clin Epidemiol 2014;6:423-32.
3. Kim H, Chung JH. Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK
rearrangement. Transl Lung Cancer Res 2015;4:149-55.
4. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553:446-54.
5. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-44.
6. Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, et al. The international epidemiology of lung cancer: latest trends, disparities,
and tumor characteristics. J Thorac Oncol 2016;11:1653-71.
7. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, et al. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb
Mol Case Stud 2017;3:a001115.
8. Webb TR, Slavish J, George RE, Look AT, Xue L, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule
inhibitor development for therapy. Expert Rev Anticancer Ther 2009;9:331-56.
9. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed
specifically in the nervous system. Oncogene 1997;14:439-49.
10. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell
lung cancer. Nature 2007;448:561-6.
11. Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol 2016;27 Suppl 3:iii4-15.
12. Ou SI, Shirai K. Anaplastic lymphoma kinase (ALK) signaling in lung cancer. Adv Exp Med Biol 2016;893:179-87.
13. Iyevleva AG, Raskin GA, Tiurin VI, Sokolenko AP, Mitiushkina NV, et al. Novel ALK fusion partners in lung cancer. Cancer Lett
2015;362:116-21.
14. Sabir SR, Yeoh S, Jackson G, Bayliss R. EML4-ALK variants: biological and molecular properties, and the implications for patients.
Cancers (Basel) 2017;9:118.
15. Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, et al. EML4-ALK fusion variant V3 is a high-risk feature conferring
accelerated metastatic spread, early treatment failure and worse overall survival in ALK + non-small cell lung cancer. Int J Cancer
2018;142:2589-98.
16. Shaw AT, Solomon B. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. Available from: https://
www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer. [Last accessed on 16
Jan 2019]
17. Wu YC, Chang IC, Wang CL, Chen TD, Chen YT, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK
rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One 2013;8:e70839.
18. Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in
European NSCLC patients: results from the European thoracic oncology platform lungscape project. J Thorac Oncol 2018;13:413-25.
19. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, et al. Systemic therapy for stage IV non-small-cell lung cancer: American society of
clinical oncology clinical practice guideline update. J Clin Oncol 2017;35:3484-515.
20. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, et al. Systemic therapy for stage IV non-small-cell lung cancer: American
society of clinical oncology clinical practice guideline update. J Clin Oncol 2015;33:3488-515.
21. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann Oncol 2016;27:v1-27.
22. ChenY, Fu L. Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B 2011;1:197-207.
23. Remon J, Besse B. Brain metastases in oncogene-addicted non-small cell lung cancer patients: incidence and treatment. Front Oncol
2018;8:88.
24. Rocco D, Battiloro C, Della Gravara L, Gridelli C. Safety and tolerability of anaplastic lymphoma kinase inhibitors in non-small-cell lung
cancer. Drug Saf 2018; doi: 10.1007/s40264-018-0771-y.
25. Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, et al. FDA approval summary: crizotinib for the treatment of metastatic non-
small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist 2014;19:e5-11.
26. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J
Med 2014;371:2167-77.
27. Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. Final overall survival analysis from a study comparing first-line crizotinib
versus chemotherapy in alk-mutation-positive non-small-cell lung cancer. J Clin Oncol 2018;36:2251-8.
28. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-
rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet 2017;389:917-29.
29. Camidge RD, Peters S, Mok T, Gadgeel SM, Cheema PK, et al. Updated efficacy and safety data from the global phase III ALEX study of
alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK + NSCLC. J Clin Oncol 2018;36:9043.